Monitor for any subsequent filings (e.g., 8-Ks, proxy statements) that may reveal strategic rationale behind the board refresh, potential activist involvement, or changes in corporate strategy. The reduction in board size and appointment of new directors with Big Pharma and public-company CFO backgrounds could signal a pivot toward operational discipline or a potential sale process.
Price Chart
Executive Summary
Cue Biopharma announced the immediate resignation of four board members (Jill Broadfoot, Peter Kiener, Frank Morich, Patrick Verheyen) and a reduction in board size from seven to five directors, effective June 1, 2026. Simultaneously, the company appointed two new directors (Daniel Camardo, Viola Meehan), a new Chief Legal & Compliance Officer (Sumita Ray), and a new VP/Principal Accounting Officer (Michael Meluzio). These sweeping governance changes, while not due to any disclosed disagreement, represent a significant board refresh and restructuring of leadership roles at a $97M market cap clinical-stage biotech.
Key Facts
- Four directors (Broadfoot, Kiener, Morich, Verheyen) resigned immediately on May 29, 2026, with no disagreement disclosed.
- Board size reduced from seven to five directors, effective June 1, 2026.
- Daniel Camardo and Viola Meehan appointed as directors on May 30, 2026, for one-year terms.
- Sumita Ray appointed Chief Legal & Compliance Officer and Corporate Secretary, effective June 1, 2026.
- Michael Meluzio appointed VP, Principal Accounting Officer, effective June 1, 2026, with no additional compensation.
- Colin Sandercock continues as SVP, Intellectual Property.
- Shao-Lee Lin remains President and CEO, also serving as Interim Principal Financial Officer and Interim Principal Accounting Officer.
Financial Impact
No financial figures disclosed; governance restructuring with no stated costs or material financial impact.
Risk Factors
- Board departures without disclosed disagreement could mask underlying strategic or governance tensions.
- Reduced board size concentrates decision-making power, increasing key-person risk.
- No financial guidance or pipeline updates were provided, leaving fundamental outlook unchanged.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-253709 |
| Document: 0001193125-26-253709-index-headers.html | 0001193125-26-253709 |
| Document: 0001193125-26-253709-index.html | 0001193125-26-253709 |
| Document: 0001193125-26-253709.txt | 0001193125-26-253709 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | Insider Cluster | $18.67 $16.71 | ▲ +10.50% | ▲ +9.39% | $18.43 (+1.29%) |
Oct 13, 2026 12d ago | 144 | $18.60 $18.67 | ▲ +0.38% | ▲ +0.09% | $18.43 (−0.91%) |
Oct 8, 2026 18d ago | SC 13G/A | $22.33 $27.66 | ▲ +23.87% | ▲ +23.27% | $18.43 (−17.47%) |
Sep 21, 2026 5w ago | 8-K | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.43 (−34.81%) |
Sep 20, 2026 5w ago | Press Release | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.43 (−34.81%) |
Aug 21, 2026 9w ago | EFFECT | $23.98 $23.18 | ▲ +3.34% | ▲ +3.04% | $18.43 (+23.14%) |
Aug 17, 2026 9w ago | Insider Cluster | $25.70 $26.28 | ▼ −2.26% | ▼ −2.05% | $18.43 (+28.29%) |
Aug 14, 2026 10w ago | Press Release | $27.64 $25.70 | ▼ −7.02% | ▼ −6.34% | $18.43 (−33.32%) |
Aug 13, 2026 10w ago | 144 | $34.20 $27.64 | ▼ −19.18% | ▼ −18.71% | $18.43 (−46.11%) |
Jul 9, 2026 15w ago | Press Release | $36.78 $30.92 | ▼ −15.93% | ▼ −15.17% | $18.43 (−49.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers